Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2026 06:39 ET | Source: Alturos Therapeutics

Alturos Therapeutics advancement of lead candidate ALT0135, a potentially first-in-class, orally bioavailable small molecule, into IND-enabling studies

Oral first-in-class neuroprotective small molecule ALT0135 moves into IND-enabling studies targeting early toxic triggers in Alzheimer’s disease.